Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
← catalyst calendarSponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
28actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-09 | actual | When the study began enrolling |
| Primary completion | 2026-04-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteer Study
- Hepatic Impairment
- Renal Impairment
Intervention
- Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination — also filed as AT-527 (BEM) and AT-038 (RZR)
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK) of BEM/RZR Maximum plasma concentration (Cmax)
measured Day 1
Pharmacokinetics (PK) of BEM/RZR Area under the plasma concentration-time curve (AUC)
measured Day 1
Pharmacokinetics (PK) of BEM/RZR AUC
measured Day 1
Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed